IDWeek 2026: early ensitrelvir PEP may benefit breakthrough and established Covid-19
At IDWeek 2026, Akimasa Fukushi from Shionogi presented a subpopulation analysis of the Phase III SCORPIO-PEP trial.
Featured s
IDWeek 2026: ISL/LEN on track to become the first once-weekly oral HIV therapy
At IDWeek 2026, Samir K Gupta presented a pooled analysis of the Phase III ISLEND-1 and ISLEND-2 trials evaluating once-weekly…
All Articles
IDWeek 2026: early ensitrelvir PEP may benefit breakthrough and established Covid-19
At IDWeek 2026, Akimasa Fukushi from Shionogi presented a subpopulation analysis of the Phase III SCORPIO-PEP trial.
IDWeek 2026: ISL/LEN on track to become the first once-weekly oral HIV therapy
At IDWeek 2026, Samir K Gupta presented a pooled analysis of the Phase III ISLEND-1 and ISLEND-2 trials evaluating once-weekly…
Prediction markets herald insider trading risks for private biotechs
Legal experts say that pharma outcome bets on platforms like Kalshi and Polymarket pose new insider trading risks.
Casgevy gains UK label expansion for younger patient population
Patients with β-thalassemia and sickle cell disease aged five and up can now receive Vertex Pharmaceuticals and CRISPR Therapeutics gene…
Eli Lilly’s tirzepatide outperforms big pharma companies in Q3
Sales for Eli Lilly’s Mounjaro and Zepbound topped $16bn, exceeding total revenue for many big pharma players.
Glenmark opens Allentown distribution hub in US
The facility functions as the company's sole distribution centre in the US.
Dren Bio raises $350m for dibotatug clinical development
Dren Bio will use the capital to progress its broader pipeline in autoimmune disorders, immunology, neurology, and oncology.
RFK Jr backs compounding of six unapproved peptides in new policy
The policy will allow compounders to use these actives in compounded medicines as wellness-focused peptides increasingly seep into the consumer…
Gaelic Labs: the EU Critical Medicines Act will have a positive impact on supply
The firm is eyeing competitive benefits from its 2025 acquisition of fellow Irish beta-lactams manufacturer and further expansion as the…
IDWeek 2026: Abrysvo data in nursing home residents could support re-vaccination
Abrysvo was first approved in the US in 2023 for the prevention of lower respiratory tract disease (LRTD) caused by RSV.